Recorded Presentation from the NCCN Pharmacy Updates: The Evolving Landscape of Maintenance Therapy for Ovarian Cancer
This webinar will discuss key concepts in maintenance therapy for ovarian cancer, review clinical efficacy and safety data on potential treatment options and identify and address special considerations for monitoring and patient/caregiver education.
Category
  • Ovarian Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Mutational Landscape in Myeloproliferative Neoplasms: Implications on Prognosis and Clinical Management
The diagnosis and management of patients with myeloproliferative neoplasms (MPN) has evolved since the identification of “driver” mutations, namely JAK2, CALR, and MPL mutations. Health care providers are challenged to stay abreast of new developments in the field that may help inform clinical decision-making.
Category
  • Myeloproliferative Neoplasms
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recommendations for Managing Adults with Histiocytic Neoplasms: New NCCN Guidelines
That patients’ signs and symptoms are often nonspecific can lead to delays in diagnosis and treatment of histiocytic disorders, and ambiguous cases should be evaluated at centers of expertise. Although challenging, it is important that clinicians remain current with advances in the management of these disorders.
Category
  • Hematologic Malignancies
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
General Principles of Biomarker Testing: When Should Broad Genomic Profiling Be Performed and What Do Different Tests Offer?
Biomarker testing is increasingly being utilized in oncology practice. Practitioners need to know the types of genetic alterations that can be detected, the technologies that can be used to detect these alterations, and the limitations of those techniques in order to ensure that their patients can be appropriately diagnosed, monitored, and matched with targeted therapies or recommended for clinical trials.
Category
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
General Principles of Test Interpretations: What Results are Actionable and How to Advise Patients About Results?
Oncologists need to be able to understand and interpret the increasingly vast and complex results that are obtained from genomic testing in order to ensure that appropriate testing is done and that the results can be effectively communicated with their patients.
Category
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Biomarkers in Solid Tumors: What’s on the Horizon?
Biomarker testing in oncology is an area of rapid growth. Practitioners need to be aware of new techniques that are being developed for detection of genomic alterations, and should also be aware of ongoing clinical trials that use novel trial designs and methodology for development of biomarker tests and targeted therapies.
Category
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: Current Challenges with Investigational Drug Services and Expanded Access Programs
It is necessary to identify the practice gaps in investigational drug services and provide solutions for better process improvement in managing clinical trials. In addition, it is important for pharmacists to be familiar with the steps that are involved in initiating expanded access programs and determine the criteria for successful enrollment and implementation of such programs.
Category
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: Understanding the Place in Therapy for an Oral LHRH Antagonist as a Treatment Option in Prostate Cancer
Relugolix has a unique place in therapy for the treatment of prostate cancer. As a first-in-class oral LHRH antagonist, relugolix provides many benefits for patients. However, it is critical to understand how to manage the potential toxicities, drug interactions and adherence issues when initiating and maintaining this new oral agent.
Category
  • Prostate Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: Not Just a Band-Aid: The Impact of Chemotherapy Dose Banding in Infants
It is important for health care professionals caring for pediatric patients with cancer to identify challenges in chemotherapy dosing for infants and smaller children, rationales for current dosing recommendations commonly utilized in clinical trials, and the potential impact of BSA-based dose banding in this specific subset of the pediatric patient population.
Category
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: Crossroads of Exercise and Chemotherapy
It is important to provide education and an action plan to outline how exercise may not only reduce side effects from chemotherapy but also help chemotherapy work better and improve survival. As new data emerges, more specific exercise “doses” can be prescribed.
Category
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation

Pages